Journal of Comprehensive Pediatrics

Published by: Kowsar

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

Viatcheslav V. Berezhnoi 1 , Marianne Heger 2 , Walter Lehmacher 3 and Georg Seifert 4 , *
Authors Information
1 Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
2 ISO-Pharmaceuticals, Ettlingen, Germany
3 Universitaet zu Koeln, Institut fuer Medizinische Statistik, Informatik und Epidemiologie, Koeln, Germany
4 Charité - Universitätsmedizin Berlin, Otto-Heubner-Center for Pediatric and Adolescent Medicine (OHC), Department of Pediatric Hematology and Oncology, Berlin, Germany
Article information
  • Journal of Comprehensive Pediatrics: November 2016, 7 (4); e42158
  • Published Online: November 24, 2016
  • Article Type: Research Article
  • Received: September 9, 2016
  • Revised: November 6, 2016
  • Accepted: December 17, 2016
  • DOI: 10.17795/compreped-42158

To Cite: V. Berezhnoi V, Heger M, Lehmacher W, Seifert G. Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis, J Compr Ped. 2016 ; 7(4):e42158. doi: 10.17795/compreped-42158.

Abstract
Copyright © 2016, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the infectious diseases society of america. Clin Infect Dis. 2012; 55(10)-102[DOI]
  • 2. Vincent MT, Celestin N, Hussain AN. Pharyngitis. Am Fam Physician. 2004; 69(6): 1465-70[PubMed]
  • 3. Pineiro Perez R, Hijano Bandera F, Alvez Gonzalez F, Fernandez Landaluce A, Silva Rico JC, Perez Canovas C, et al. [Consensus document on the diagnosis and treatment of acute tonsillopharyngitis]. An Pediatr (Barc). 2011; 75(5): 342 e1-13[DOI][PubMed]
  • 4. Zoorob R, Sidani MA, Fremont RD, Kihlberg C. Antibiotic use in acute upper respiratory tract infections. Am Fam Physician. 2012; 86(9): 817-22[PubMed]
  • 5. Hersh AL, Jackson MA, Hicks LA, American Academy of Pediatrics Committee on Infectious Diseases . Principles of judicious antibiotic prescribing for upper respiratory tract infections in pediatrics. Pediatrics. 2013; 132(6): 1146-54[DOI][PubMed]
  • 6. Janecki AJ, Kiderlen AF, Kolodziej H. In vitro evaluation of EPs® 7630 for its ability to inhibit neuraminidase using sodium (4-methyl-umbelliferyl-α -D-N acetylneuraminate) as substrate. Planta Med. 2009; 75(9)[DOI]
  • 7. Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine. 2011; 18(5): 384-6[DOI][PubMed]
  • 8. Theisen LL, Muller CP. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 2012; 94(2): 147-56[DOI][PubMed]
  • 9. Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine. 2007; 14 Suppl 6: 18-26[DOI][PubMed]
  • 10. Conrad A, Jung I, Tioua D, Lallemand C, Carrapatoso F, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine. 2007; 14 Suppl 6: 52-9[DOI][PubMed]
  • 11. Conrad A, Hansmann C, Engels I, Daschner FD, Frank U. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine. 2007; 14 Suppl 6: 46-51[DOI][PubMed]
  • 12. Neugebauer P, Mickenhagen A, Siefer O, Walger M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures--exemplary measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine. 2005; 12(1-2): 46-51[DOI][PubMed]
  • 13. Koch E, Lanzendörfer-Goossens H, Wohn C. Stimulation of interferon (INF)-beta-synthesis and natural killer (NK) cell activity by an aqueous-ethanolic extract from roots of Pelargonium sidoides (Umckaloabo®). In: Abstracts of the 43rd Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology. 12-14 March 2002, Mainz, Germany. Naunyn Schmiedebergs Arch Pharmacol. 2002; 365[PubMed]
  • 14. Witte K, Koch E, Volk HD, Wolk K, Sabat R. The pelargonium sidoides extract EPs 7630 drives the innate immune defense by activating selected map kinase pathways in human monocytes. Plos One. 2015; 10(9): 138075[DOI]
  • 15. Matthys H, Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin. 2007; 23(2): 323-31[DOI][PubMed]
  • 16. Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin. 2010; 26(6): 1413-22[DOI][PubMed]
  • 17. Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther. 2010; 48(3): 184-91[PubMed]
  • 18. Kamin W, Maydannik VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis. Acta Paediatr. 2010; 99(4): 537-43[DOI][PubMed]
  • 19. Kamin W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int. 2012; 54(2): 219-26[DOI][PubMed]
  • 20. Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore (NY). 2005; 1(6): 437-45[DOI][PubMed]
  • 21. Lizogub VG, Riley DS, Heger M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY). 2007; 3(6): 573-84[DOI][PubMed]
  • 22. Matthys H, Lehmacher W, Zimmermann A, Brandes J, Kamin W. EPs 7630 in acute respiratory tract infections - a systematic review and meta-analysis of randomized clinical trials. J Lung Pulm Respir Res. 2016; 3(1): 68[DOI]
  • 23. Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser M. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir Med. 2013; 107(5): 691-701[DOI][PubMed]
  • 24. Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med. 2003; 9(5): 68-79[PubMed]
  • 25. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977; 64(2): 191-9[DOI]
  • 26. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics. 1987; 43(1): 193-9[DOI]
  • 27. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999; 55(4): 1286-90[PubMed]
  • 28. Wassmer G, Eisebitt R, Coburger S. Flexible interim analyses in clinical trials using multistage adaptive test designs. Drug Inf J. 2001; 35(4): 1131-46[DOI]
  • 29. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004; 5(3): 445-64[DOI][PubMed]
  • 30. Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis. Appl Stat . 1994; 43(1): 49[DOI]
  • 31. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000; 1(4): 465-80[DOI][PubMed]
  • 32. Zanasi A, Lanata L, Saibene F, Fontana G, Dicpinigaitis PV, Venier V, et al. Prospective study of the efficacy of antibiotics versus antitussive drugs for the management of URTI-related acute cough in children. Multidiscip Respir Med. 2016; 11: 29[DOI][PubMed]
  • 33. Kumar R, Clermont G, Vodovotz Y, Chow CC. The dynamics of acute inflammation. J Theor Biol. 2004; 230(2): 145-55[DOI][PubMed]
  • 34. Naumann HH, Helms J, Herberhold C, Kastenbauer E. Oto-rhino-laryngologie in klinik und praxis. 1992;
  • 35. Schettler G. Innere medizin - ein kurzgefasstes lehrbuch bd.1. 1987;
  • 36. Arroll B. Antibiotics for upper respiratory tract infections: an overview of Cochrane reviews. Respir Med. 2005; 99(3): 255-61[DOI][PubMed]
  • 37. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013; (11)[DOI][PubMed]
  • 38. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH, Infectious Diseases Society of America . Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis. 2002; 35(2): 113-25[DOI][PubMed]
  • 39. Del Mar CB, Glasziou PP, Spinks AB. Review: antibiotics for sore throat reduce symptoms at day 3 and the incidence of rheumatic fever and otitis media. Evid Based Nurs. 2000; 3(3): 78[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments